This study is testing a new treatment called AlloNK®, a type of cell therapy made from umbilical cord blood, combined with an existing medicine called Rituximab. This combination is being studied in people with certain rheumatologic diseases that haven't responded well to other treatments, including Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), and Systemic Sclerosis (SSc). The main goal is to see how safe this new combination is. To join, you must be at least 18 years old and meet specific criteria for your condition, such as having a diagnosis of RA with positive Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA), and elevated inflammation markers (hs-CRP or ESR). The study plans to enroll 90 participants.

Study design

This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It is a Phase 2a study, which typically means it's an early-stage study looking at safety and effectiveness, and plans to include 90 participants.

What's involved

You would receive AlloNK after a conditioning regimen, combined with Rituximab. The study will follow you from enrollment until the end of treatment at Week 104.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be measured from enrollment until the end of treatment at Week 104.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.